In Germany, ten to twelve percent of adults older than 40 years suffer from COPD. While in 2010, 6.8 million people suffered from COPD in Germany, it is estimated that this number will increase to 7.9 million by 2030. The major factors that drive the market growth are increase in prevalence of COPD patients, increase in aging population, technological advancement in the treatment of COPD, increase in pipeline products growth, initiatives implemented by the government and non-government associations for rising in health awareness. Visit https://insights10.com/ for more healthcare industry insights.

1. Germany Chronic
Obstructive Pulmonary
Disease (COPD) Market
Analysis
Germany COPD Market Analysis including Market Size,
Epidemiology and Market Segmented by Treatment Type, Drug
Class, Distribution Channel and Key Competitors
(Data forecasts from 2020 – 2028)

2. 2 Confidential
Table of content
1. Methodology and Scope……………………………………………………………………………………………………………….….…………………………………04
a. Research Methodology
b. Research Approach
c. Key Benefit for Stakeholders from this report
2. Germany COPD Market Analysis: Market Overview…………………………………………………………………………………………………………………….08
a. Germany COPD Market Analysis (Current and Forecasted)
3. Germany COPD Epidemiology ……………………………………………………………………………………………………………………………………………..10
a. Germany COPD Prevalence
b. Germany COPD Incidence
c. Regional Differences
4. Germany COPD Market Analysis: Growth Drivers & Restraints……………………………………………………………………………………………………….14
a. Market Growth Drivers and Restraints
i. Prevalence of COPD Patients
ii. Increase in Ageing Population
iii. Government Initiatives
iv. Technological Advancements
v. Growth of Pipeline Products
b. Market Restraints
i. Stringent Government Approvals
ii. Side effects associated with the drugs

3. 3 Confidential
Table of content (continued)
5. Germany COPD Market Analysis: Market Segmentation……………………………………………………………………………………………………………….22
a. Germany COPD Market Segmentation
i. Market Segmentation: By Treatment Type
ii. Market Segmentation: By Drug Class
iii.Market Segmentation: By Distribution Channels
6. Germany COPD Market Analysis: COPD Major Products Market Share…………………………………………………………………………………………….27
a. Market Analysis, Insights and Forecast- By Revenue
7. Germany COPD Market Analysis: Competitive Landscape…..………………………………………………………………….….…………………………………29
a. Competitive Landscape: Key Players Revenue(Current and Forecasted)
8. Key Companies profile………………………………………………..……………...……………………………………………………………………………...……….31
a. Mylan N.V.
b. GlaxoSmithKline plc
c. Boehringer Ingelheim
d. Teva Pharmaceuticals
e. AstraZeneca
9. Healthcare Policy and Regulatory Landscape ……………………………………………………………………….………………………………………………….42
a. Policy Changes and Reimbursement In Germany COPD Market
10.Future Development Growth……………………….………………..……………...……………………………………………………………………………...……….44
a. Future Opportunities

4. Methodology and Scope

5. 5 Confidential
Methodology and Scope
Research Methodology
 Insights 10’s research methodology delves deep into the market, covering the macro and micro aspects of the industry. We identify the key growth drivers,
opportunities, and restraints that might promote or hinder the future industry growth along with an expansive overview of the competitive landscape to help our
clients make informed strategic decisions
 We implement a mix of primary and secondary research for our market estimate and forecast. The secondary research forms the initial phase of our study
where we conducted extensive data mining, referring to verified data sources such as independent studies, government and regulatory published material,
technical journals, trade magazines, and paid data sources
 For forecasting, the following parameters were considered:
 Market drivers and restraints along with their current and expected impacts
 Technological scenario and expected developments
 End use industry trends and dynamics
 Trends in the consumer behavior
 Regulatory scenario and expected developments
 Current capacity and expected capacity additions up to 2028
 We have assigned weights to these parameters and quantified their market impacts using the weighted average analysis to derive the expected market growth
rate
 We appoint data triangulation strategies to explore different areas of the market. Our qualitative and quantitative assessments are time-sensitive, reflecting the
most recent value and volume of the market across regions
 All our estimates and forecasts were verified through exhaustive primary research with the Key Industry Participants (KIPs)

6. 6 Confidential
• The information gathered is then analyzed and synthesized. The
market research report is presented in different forms such as charts
by using a scientific approach for easy understanding
• Market Trends such as Drivers, Restraints, Opportunities,
Challenges. An intensive cross-verification and validation process
• Company Reports and Publications, Government Data, Financial
Reports of Key Industry Players, Press Releases, Scientific and
Industry Publications and Whitepapers
Methodology and Scope (continued)
Analysis Methodology
The data presented is comprehensive, reliable, and the result of extensive research, both primary and secondary
Data Collection
• Primary Interviews
• Secondary Data
Market Data Analysis &
Statistical Model
• Market Trends
• Market Sizing and Analysis
• Data Triangulation & Validation
Interpretation and
Presentation
• Analysis & Interpretation
• Insights
• Presentation & Reporting

7. 7 Confidential
Methodology and Scope (continued)
The study provides an in-depth analysis of the Germany Chronic Obstructive Pulmonary Disease (COPD), market with current
trends and future estimations to elucidate the imminent investment pockets
Key Benefit for Stakeholders from this report
Our tools provides stakeholders with a cohesive understanding of the industry outlook, considering the qualitative and
quantitative industry variables
Comprehensive analysis of factors that drive and restrict the market growth is provided
Comprehensive quantitative analysis of the industry from 2020 to 2028 is provided to enable the stakeholders to capitalize on
the prevailing market opportunities
Extensive analysis of the key segments of the industry helps understand the applications and technologies used globally
Our rigorous data collection, thorough statistical analysis and specialist assessments ensure that our clientele has a greater
understanding of the industry space, supply chain, price fluctuations, competitive landscape, and other vital factors

8. Germany COPD Market Analysis: Market
Overview

9. 9 Confidential
Germany COPD Market Analysis (Current and Forecasted)
Germany COPD Market Size (Mn) 2020-2028F
 Germany’s COPD market size stood at around USD 617
million in 2020 and is projected to reach USD XX million by
2028, exhibiting a CAGR of around XX.X% during the
forecast period
 According to several estimates, in Germany, 10-12% of
adults older than 40 years are suffering from COPD and this
number could increase to 24%
 Tobacco smoke and the inhalation of heavily contaminated
fine dust has been identified as the primary cause for the
development of COPD in Germany
 However, it has been shown that also passive smoking can
be a triggering factor as well as air pollution at the
workplace caused by chemicals and dust
 COPD is also one of the most prevalent occupational
diseases in Germany
2020 2021 2022 2023 2024 2025 2026 2027 2028
Key Analysis
$617Mn

10. Germany COPD Market Analysis: Epidemiology

11. 11 Confidential
Germany COPD Prevalence
Germany COPD Prevalence 2020-2028F
 In 2020, around 5.7 Mn were suffering from COPD
accounting for a prevalence rate of 7.1%
 Over the coming years, the prevalence is expected to
decline slightly owing to increasing access to required
medications
2020 2021 2022 2023 2024 2025 2026 2027 2028
Key Analysis
5,771,496
XX
Sample

12. 12 Confidential
Germany COPD Incidence
Germany COPD Incidence 2020-2028F Key Analysis
2020 2021 2022 2023 2024 2025 2026 2027 2028
Incedence of COPD
376,750
XX
 In 2020, around 377K new cases of COPD were identified
in Germany, accounting for an incident rate of 0.45%
 Over the coming years, the incident cases are expected to
decline slightly owing to increasing access to required
medications
Sample

13. 13 Confidential
Distribution of Prevalence of COPD Across Germany Key Analysis
Significant regional differences can be seen in prevalence and incidence
of COPD across Germany
 According to a study the lowest COPD percentage in
Germany is found in the Baden-Württemberg district of
Biberach, at 4.1%, and the highest in the North Rhine-
Westphalian city of Gelsenkirchen with 12.1%
 In 2019, around 149,000 people aged 40 and over
were diagnosed with COPD in Saxony with prevalence of
6.0%
 Berlin is the negative leader with a prevalence of 8.6%,
while the national average is 7.1 percent
Sample

14. Germany COPD Market Analysis : Growth Drivers
And Growth Restraints

15. 15 Confidential
Market Growth Drivers And Restraints
Prevalence of COPD
Patients
Government
Initiatives
Impact
Market
Drivers
Increase in Ageing
Population
Technological
Advancement
Pipeline
Product Growth
Stringent Government
Regulations for Product
approval
Side Effects Associated
With Drugs
Market
Restraints
Impact
Impact

16. 16 Confidential
Market Growth Drivers
1. Increasing prevalence of COPD among Germans
Germany is ranked in the group of countries presenting highest prevalence of COPD, with current prevalence estimates range from 1.3% to
13.2% on basis of various sources
Results from international surveys including data from Germany reveal a higher prevalence of Spiro metrically defined COPD among men than
among women. The estimated prevalence of Spiro metrically defined COPD among adults 40 year of age or older was 9.3% for women and
18.1% for men based on data collected in the German Study Centre Hanover of the international Burden of Obstructive Lung Disease (BOLD)
Sample

17. 17 Confidential
Market Growth Drivers (continued)
Ageing is one of the main driving forces of the development and increasing burden of noncommunicable diseases including COPD. Elderly
COPD patients are characterized by a complexity due to an increasing prevalence of comorbidities related to the age that suggest peculiar
care in prescribing the therapy in those patients
Germany is currently one of only five “super-aged” societies in the world, and its population of those age 65 and older will continue to grow,
reaching nearly one-third of the total population by 2050
Germany’s population age 65 and older is projected to grow by 41% to 24 million by 2050, accounting for nearly one-third of the total
population. At the same time, the population ages 15 through 64 will shrink by 23% – from about 53 million in 2015 to about 41 million by 2050
2. Increase in Ageing population

18. 18 Confidential
Market Growth Drivers (continued)
3. Government Initiatives
German Government initiated the German National Guideline for Treating Chronic Respiratory Failure with Invasive and Non-Invasive
Ventilation for the treatment of chronic obstructive pulmonary disease (COPD)
The DMP for COPD was developed by the Federal Joint Committee (Gemeinsamer Bundesausschuss) and introduced in Bavaria in April 2006.
The aim was to improve care by establishing standards for diagnosis, treatment, documentation, quality assurance, and referral, while
enhancing active patient participation
Sample

19. 19 Confidential
Market Growth Drivers (continued)
4. Technological Advancement
Sample
Sample
Sample

20. 20 Confidential
Market Growth Drivers (continued)
5. Pipeline Product Growth (for both devices and drugs)
Currently the metered dose inhalers (MDI), drug powder inhalers (DPI) and soft mist inhalers (SMI) market (for both asthma and COPD
combined) made up ~$2 billions in 2020 and this will grow at a CAGR of 7.3% during 2020 to 2028
Sample
Sample

21. 21 Confidential
Stringent Government regulations and Product
Approval
Side Effects Associated with Drugs
Market Restraints
 The pharmacotherapy received by a large
proportion of COPD patients in Germany differs
from what one would normally expect
 Two thirds of German COPD patients received
an Inhaled Corticosteroids (ICS) which,
however, was not indicated in about half of
these cases according to the latest international
treatment recommendations
 This deviation is relevant not only because of
the costs of ICS, but also because of the
significant potential side effects associated with
inhaled corticosteroids
Sample

22. Germany COPD Market Analysis : Market
Segmentation

23. 23 Confidential
Germany COPD Market Segmentation
By Treatment Type
Germany COPD Market Segmentation
By Drug Class By Distribution Channel
Bronchodilator
Monotherapy
Anti-inflammatory drugs
Combination
Phosphodiesterase Type 4
Inhibitors
Mucokinetics
Corticosteroids
Online Pharmacies
Hospital Pharmacies
Retail Pharmacies

24. 24 Confidential
 The German COPD Market is segmented into
Bronchodilator, Monotherapy and Anti-inflammatory drugs
by treatment type
 Bronchodilator can be further sub categorized into Short-
Acting Beta-2 Agonists, Long-Acting Beta-2 Agonists and
Anticholinergic Agents
 Anti-inflammatory drugs can be further sub categorized
into Oral and Inhaled Corticosteroids, Anti-leukotrienes,
Phosphodiesterase Type-4 Inhibitors and Other Anti-
inflammatory Drugs
Market Segmentation: By Treatment Type
German COPD Market Share by Treatment Type 2020
Key Insights
Bronchodilator
Monotherapy
Anti-inflammatory drugs

25. 25 Confidential
Market Segmentation: By Drug Class
German COPD Market Share
By Drug Class 2020
 The German COPD Market is segmented into
phosphodiesterase Type 4 inhibitors, Combination,
Mucokinetics and Corticosteroids by drug class
 The lack of effective anti-inflammatory drug treatment for
COPD has thus shifted the interest in development toward
COPD
Key Insights
Combination Phosphodiesterase Type 4 Inhibitors
Mucokinetics Corticosteroids

26. 26 Confidential
Market Segmentation: By Distribution Channels
German COPD Market Share by Distribution Channel 2020
 The German COPD Market is segmented into Online
Pharmacies, Hospital Pharmacies and retail Pharmacies
by the Distribution Channels
Key Insights
Online Pharmacies
Hospital Pharmacies
Retail pharmacies

27. Germany COPD Market Analysis : COPD Major
Products Market Share

28. 28 Confidential
 Among the EU5 countries, Germany had the highest market
size with USD 617 million in 2020, while United kingdom
had the lowest market size of COPD with USD 274 million
each, in 2020
 As per the National Institute of Health Research 2019, the
prevalence of Chronic obstructive pulmonary disease
(COPD) in Germany is around 2.7 million
 In addition, according to the Global Health Data Exchange,
in 2017 approximately 575,558 people are affected by
COPD in Germany
 Thus, the presence of such a large number will demand
respiratory devices and drive the market in Germany
 The Germany Respiratory Devices Market is expected to
register a CAGR of 5.5% during the forecast period
Market Analysis, Insights and Forecast- By Revenue
Key Insights
German COPD Major Market Share for respiratory
devices
Sample

29. Germany COPD Market Analysis : Competitive
Landscape

30. 30 Confidential
Competitive Landscape: Key Players Revenue (Current and Forecasted)
2020 2021F 2022F 2023F 2024F 2025F 2026F 2027F 2028F
Mylan N.V. XX - - - - - - - -
GlaxoSmithKline plc. XX - - - - - - - -
Boehringer Ingelheim XX - - - - - - - -
Teva Pharmaceuticals XX - - - - - - - -
AstraZeneca XX - - - - - - - -
Major Market Revenue of Germany COPD Market ($Bn)

31. Key Company Profiles

32. 32 Confidential
Mylan N.V.
Company Profile
 The company was founded in 1961 and developed and
produced medicines for a wide range of medical disciplines,
including oncology, anaphylaxis, antiretrovirals, cardiovascul
ar, respiratory, dermatology, immunology, anesthesia and pa
in management, infectious disease, gastroenterology,
diabetology/endocrinology, and women's healthcare
 Mylan N.V. along with Theravance Biopharma got regulatory
approval in 2018 for their treatment for chronic obstructive
pulmonary disease (COPD)
Company Name: Mylan N.V.
Year of Establishment: 1961
Headquarter: Canonsburg, Pennsylvania,
United States
Revenue: $2.97 Bn
Website:https://www.mylan.com/

33. 33 Confidential
Mylan N.V. (continued)
Breakdown of net revenue by segment, 2020
 When Yupelri was first approved in November 2018, Mylan, now Viatris, focused on educating healthcare professionals about the new COPD
treatment option, using sales rep in-person meetings and digital ads before tackling DTC advertising
 Yupelri is a long-acting muscarinic antagonist and the first once-a-day nebulized maintenance medicine for COPD. Mylan and Theravance share profit
and loss on Yupelri in a 65% to 35% split, respectively.
 Sales of Yupelri topped $37 million for the third quarter, up 124% over the same quarter in 2020, rebounding after a dip during the second quarter
XX
Analysis
Revenues ($Bn), 2020-2028

34. 34 Confidential
Sample
Company Name: GlaxoSmithKline plc
Year of Establishment: 2000
Headquarter: London, England
Revenue: $43.783 Mn
Website: https://www.gsk.com/en-gb/home/
Company Profile
GlaxoSmithKline plc

35. 35 Confidential
Breakdown of net revenue (%) by segment, 2020
Analysis
Sample
Revenues ($Bn), 2020-2028
GlaxoSmithKline plc

36. 36 Confidential
Sample
Company Name: Boehringer Ingelheim
Year of Establishment: 1885
Headquarter: Ingelheim am Rhein, Germany
Revenue: $22.33 Bn
Website:https://www.boehringer-ingelheim.com/
Company Profile
Boehringer Ingelheim

37. 37 Confidential
Breakdown of net revenue (%) by segment, 2020
Analysis
Sample
Revenues ($Bn), 2020-2028
Boehringer Ingelheim

38. 38 Confidential
Sample
Company Name: Teva Pharmaceuticals
Year of Establishment: 1901
Headquarter: Jerusalem, Israel
Revenue: $16.7 Bn
Website: https://www.tevapharm.com/
Company Profile
Teva Pharmaceuticals

39. 39 Confidential
Breakdown of net revenue (%) by segment, 2020
Analysis
Sample
Revenues ($Bn), 2020-2028
Teva Pharmaceuticals

40. 40 Confidential
Sample
Company Name: AstraZeneca
Year of Establishment: 1999
Headquarter: Cambridge, United Kingdom
Revenue: $25.890 Bn
Website:https://www.astrazeneca.com/
Company Profile
AstraZeneca

41. 41 Confidential
Breakdown of net revenue (%) by segment, 2020
Analysis
Sample
Revenues ($Bn), 2020-2028
AstraZeneca

42. Healthcare Policy and Regulatory Landscape

43. 43 Confidential
Policy Changes and Reimbursement Scenario in Germany COPD Market
 To curb costs and improve health outcomes in chronic obstructive pulmonary disease (COPD), a nationwide disease management
programme (DMP) was introduced in Germany in 2005
 The primary aim of the disease management program (DMP) for patients with COPD is to improve health outcomes and thereby to
reduce overall costs
 The German DMP for COPD has been effective in enhancing the quality of care regarding an improved adherence to guidelines,
pharmacotherapy, exacerbations, and self-management education
 In search of cost-effective concepts of chronic care management, researchers and policy-makers have increasingly recognized the
potential of telemedicine in reducing morbidity and mortality, as well as healthcare utilization and its associated costs
Sample

44. Future Development Growth

45. 45 Confidential
Future Opportunities
Bronchodilator therapy forms the mainstay of treatment for people with COPD. Bronchodilators work by altering the airways’
smooth muscle tone, leading to widening of the airways, which, in turn, improves expiratory flow
New-generation propellant-free inhaler is driven by the desire to solve patients’ problems with existing inhalers while maintaining
a low carbon footprint
Sample
Sample
Sample
Sample